Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3121-3130 Newer>

BusinessWeek September 25, 2006 Catherine Arnst	Chicken Soup For The Aging Brain The disputed idea that mental exercise can turn back time has launched an industry.
BusinessWeek September 25, 2006	How We Looked Inside Details of the analysis used to highlight the health-care sector's place in the total workforce.
The Motley Fool September 15, 2006 Brian Lawler	Glaxo's Burgeoning Blockbuster With a deep drug pipeline filled with potential blockbusters for nearly every major disease, and an attractive 3% dividend yield, Glaxo makes a fine investment opportunity for investors willing to brave the pharmaceutical sector.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool September 13, 2006 Brian Lawler	What to Make of Bristol-Myers Take a good look at the industry to try to sort out the meaning of all the news and the rumors. Investing in a company based on a possible buyout is never a good idea when the possibility is based solely on rumors and analyst speculation.
The Motley Fool September 12, 2006 Brian Lawler	Glaxo's Big Tax Bill The pharmaceutical finally decided to pay up and settle its long-running tax dispute with the IRS for $3.1 billion.
Fast Company September 2006 Tonya Garcia	Miracle Microbes In the labs of Amyris Biotechnologies, molecular manipulation may yield cheap and effective malaria drugs.
Fast Company September 2006 Paul Lukas	Halcyon Hospitals In most respects, the Dream Hospital of 1953 barely hinted at future advances. But the biggest challenge hospitals may face is that medical advances could render entire wards -- and profit centers -- obsolete.
The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
<Older 3121-3130 Newer> Return to current articles.